Eli Lilly and Company – consensus points to potential upside of 16.4%

Eli Lilly and Company, ticker code (LLY), now has 24 verified analysts covering the stock, with consensus suggesting a rating of Buy. The range between the high target and the low target is between 444 and 270, with the average target price being $380.75. Given that the stock’s previous close was $327.07, this would suggest that there is potential upside of 16.4%. There is a 50-day moving average of $337.89 and the 200-day MA is $332.90. The company’s total market capitalization now stands at $313,770 million. For more information, visit: https://www.lilly.com

The potential market cap would be $365,267 million according to the market consensus.

You can now share this on Stocktwits, just click on the logo below and paste the ticker into the text to be seen.

Eli Lilly and Company discovers, develops and markets medicines for human use worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamin, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R and Humulin U-500 for diabetes; and Jardiance, Trajenta and Trulicity for type 2 diabetes. The company offers Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza in metastatic gastric cancer, gastroesophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer and hepatocellular carcinoma; Erbitux for colorectal cancer and various types of head and neck cancer; Retevmo in metastatic NSCLC, medullary thyroid cancer and thyroid cancer; Tyvyt for relapsed or refractory classical Hodgkin lymph and non-squamous NSCLC; and Verzenio for HR+, HER2-metastatic, lymph node-positive, and early-stage breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondylarthritis. The Company offers Cymbalta for major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia and chronic musculoskeletal pain; Emgality to prevent migraines and episodic cluster headaches; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. bamlanivimab and etesevimab and bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company works with Incyte Corporation; Boehringer Ingelheim Pharma; AbCellera Biologics Inc.; Junshi Life Sciences; Regor Therapeutics Group; Lycia therapeutics; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

READ :  My Big Fat Greek Wedding 3 release date is set for September

The company has a dividend yield of 1.39% with the ex-dividend date set for 14-2-2023 (DMY).

Other notable data points include a P/E of 47.27, sales per share of 31.65, and an 11% return on assets.